These findings suggest the potential of using fat-free ApoA1 therapy and dietary adjustments to regulate the conversion between Treg and Tfh cells, offering potential benefits to patients with atherosclerosis and other inflammatory diseases. This evidence concerns the gene APOA1 and atherosclerosis.